It has also been suggested that IL-2/CD40 or IL-15/CD40 combination therapy may be more effective than anti-CD40 alone for the advanced treatment of solid tumors, including renal cell carcinoma (Piechutta and Berghoff, 2019). This evidence concerns the gene CD40 and renal cell carcinoma.